Patent application number | Description | Published |
20120263757 | COMPOSITION AND METHOD FOR DIAGNOSIS AND IMMUNOTHERAPY OF PROSTATE CANCER - A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant AKAP-4 tumor-associated antigen loaded antigen presenting cell that generates an AKAP-4 specific cytotoxic T lymphocyte specific for one or more prostate cancer cells. | 10-18-2012 |
20140243275 | Galectin-3C Combination Therapy for Human Cancer - The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses. | 08-28-2014 |
20150056252 | Composition and Method for Diagnosis and Immunotherapy of Lung Cancer - The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells. | 02-26-2015 |
20150098925 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES USING DISEASE-SPECIFIC PROMOTER - The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that the promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body. The disease-specific promoter may be the promoter of the LOX1 gene. The therapeutic agent may be Interleukin 10 (IL10). | 04-09-2015 |
20150157691 | Galectin-3 to Treat Ovarian Cancer - The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt/NF-κB activation of the ovarian cancer. | 06-11-2015 |
20150216931 | GALECTIN-3 INHIBITOR (GAL-3M) IS ASSOCIATED WITH ADDITIVE ANTI-MYELOMA AND ANTI-SOLID TUMOR EFFECTS, DECREASED OSTEOCLASTOGENESIS AND ORGAN PROTECTION WHEN USED IN COMBINATION WITH PROTEASOME INHIBITORS - The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor. | 08-06-2015 |
20150216999 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES USING SMAD3 - The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that any disease specific promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body. The disease-specific promoter may be the promoter of the LOX1 gene. The invention also provides for constitutive promoters. The therapeutic agent may be, for example, Interleukin 10 (IL10) or a member of a transforming growth factor beta 1 (TGFβ1) signaling pathway, such as mothers against decapentaplegic homolog 3 (SMAD3). | 08-06-2015 |